Contralateral Breast Cancer Risk Among Carriers of Germline Pathogenic Variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2 Between July 2013 and August 2018, 107 patients were enrolled and received ...

Phase II Study of Samotolisib in Children and Young Adults With Tumors Harboring Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Pathway Alterations: Pediatric MATCH APEC1621D MDM2, a negative ...

Promising Biomarker Reductions: Treatment with the MDM2 inhibitor navtemadlin led to significant reductions in key biomarkers of disease severity, including circulating CD34+ cells, a hallmark of ...

Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, ...

This article and associated images are based on a poster originally authored by Sarona Jacob Anderson and presented at ELRIG Drug Discovery 2025 in affiliation with University of Salford. This poster ...

CLEVELAND, OHIO, UNITED STATES, November 3, 2025 / EINPresswire.com / -- Lamassu Biotech, a clinical-stage pharmaceutical company, today announced a significant clinical milestone in its Phase 1/2a ...

--Ascentage Pharma, a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for hematological malignancies, ...

ROCKVILLE, Md. and SUZHOU, China, June 02, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (AAPG) (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs ...

Previous research revealed that nuclear factor of activated T cells 1 (NFAT1) is a novel regulator of the mouse double minute 2 homolog (MDM2) oncogene, which acts by directly binding to the MDM2 P2 ...

Co-first author Shiekh Tanveer Ahmad, PhD, co-senior author Hong Lin, PhD, co-author Jennifer Hadley and senior co-corresponding author Paul Northcott, PhD, St. Jude Center of Excellence in ...